Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 25;13(1):137–146. doi: 10.1111/cts.12694

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Relative abundance of metabolomic markers of methotrexate (MTX) response. The normalized peak ion intensity plots for the eight metabolites identified by univariate and multivariate analyses are presented. (a) Metabolites found to be increased in MTX‐treated cells includes ketoisovaleric acid, fructose, galactose, and 2‐deoxyuridine. (b) Metabolites found to be decreased in MTX‐treated cells includes 2‐deoxycytidine, phosphatidylinositol (PI) 32:0, orotic acid, and inosine monophosphate (IMP). Normalized peak ion intensity data were collected from 10 samples per group over three independent experimental evaluations. Data points and representative box and whisker plots are shown based on metabolomics analysis after 24 hours of exposure to either vehicle control or 1,000 nM MTX. Normalized peak ion intensities were compared between groups using unpaired nonparametric analysis with unequal variances. The resulting false discovery rate adjusted P values are provided.